Clinical Trials Sponsored by C3i Center Inc.

Total 4882 results

Ciusss de L'Est de l'Île de Montréal
Celgene; C3i Center Inc.

Active, not recruiting

Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant

Multiple Myeloma | Relapsed Hematologic Malignancy

Canada
Ciusss de L'Est de l'Île de Montréal
ExCellThera inc.; Centre C3i

Active, not recruiting

ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

Multiple Myeloma

Canada
M.D. Anderson Cancer Center
CTI BioPharma

Terminated

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
CTI BioPharma

Completed

CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer

United States
M.D. Anderson Cancer Center
CTI BioPharma

Terminated

Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)

Myeloproliferative Diseases

United States
M.D. Anderson Cancer Center
CTI BioPharma

Completed

Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients

Multiple Myeloma | Stem Cell Transplantation

United States
Spectrum Pharmaceuticals, Inc
CTI BioPharma

Terminated

Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)

Lymphoma, Follicular | Follicular Lymphoma

United States
M.D. Anderson Cancer Center
Biogen; CTI BioPharma

Completed

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

Lymphoma

United States
CRI Lifetree
Nuvo Research Inc.

Completed

Evaluation of the Depth and Duration of Anesthesia From Heated Lidocaine/Tetracaine (Synera®) Patches Compared With 5% Lidocaine (Lidoderm®) Patches Applied to Healthy Adult Volunteers

Healthy

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Completed

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Hodgkin Lymphoma, Adult

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Terminated

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids (NRR)

Graft Versus Host Disease

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Recruiting

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
Veracyte, Inc.

Recruiting

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA (HARMONY)

Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Lymphoma | Lymphatic Diseases | Adult T-Cell Leukemia/Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Completed

Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation

Hematologic Malignancies | Malignant Solid Tumor

United States
Jonsson Comprehensive Cancer Center
Celgene Corporation; CTI BioPharma

Terminated

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
UNC Lineberger Comprehensive Cancer Center
American Cancer Society, Inc.

Completed

Chemotherapy-related Cognitive Impairment and Acute Leukemia

Acute Myeloid Leukemia

United States
UNC Lineberger Comprehensive Cancer Center
G1 Therapeutics, Inc.

Recruiting

Study of Trilaciclib and Lurbinectidin

Lung Cancer | Small-cell Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Cerulean Pharma Inc.

Terminated

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

Rectal Cancer

United States
UNC Lineberger Comprehensive Cancer Center
AstraZeneca; Rgenix, Inc.

Recruiting

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Non-Small Cell Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

Follicular Lymphoma | Burkitt Lymphoma | Diffuse Large B-cell Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
Pfizer; American Cancer Society, Inc.

Completed

Patient-centered Communication About Healthy Weight in Early Breast Cancer

Breast Cancer

United States
Dartmouth-Hitchcock Medical Center
CTI BioPharma

Completed

Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)

Advanced Non-small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Seagen Inc.

Recruiting

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Metastatic Solid Tumor | Brain Metastases

United States
Bhavana Bhatnagar
CTI BioPharma

Completed

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia

United States
West Cancer Center
Puma Biotechnology, Inc.; Celcuity Inc

Active, not recruiting

Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2)

Triple Negative Breast Cancer | HER2-positive Breast Cancer | Early-stage Breast Cancer

United States
MaxCyte, Inc.
CTI Clinical Trial and Consulting Services

Terminated

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Fallopian Tube Adenocarcinoma | Peritoneal Mesothelioma | Primary Peritoneal Carcinoma | Adenocarcinoma of the Ovary

United States
Arog Pharmaceuticals, Inc.
Centre Leon Berard; Fox Chase Cancer Center

Unknown

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

GIST With D842V Mutated PDGFRA Gene

United States, France, Spain, Italy, Germany, Norway, Poland
DiscGenics, Inc.
CTI Clinical Trial and Consulting Services

Completed

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

Degenerative Disc Disease

United States
UNC Lineberger Comprehensive Cancer Center
Pfizer; BioMed Valley Discoveries, Inc

Recruiting

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Melanoma | Pancreatic Cancer | Tumor, Solid

United States
UNC Lineberger Comprehensive Cancer Center
Astellas Pharma Global Development, Inc.

Completed

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Non Small Cell Lung Cancer

United States
West Michigan Cancer Center
Ethicon, Inc.

Recruiting

Use of Stratafix Symmetric™ to Prevent Incisional Hernia in Gastrointestinal and Abdominal Surgery (STRATA-G)

C.Surgical Procedure; Disruption of Wound, Suture

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Recruiting

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center
Seagen Inc.

Recruiting

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Mycosis Fungoides

United States
Jonsson Comprehensive Cancer Center
Genentech, Inc.

Completed

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Glioblastoma | Gliosarcoma | Giant Cell Glioblastoma

United States
M.D. Anderson Cancer Center
Seagen Inc.

Active, not recruiting

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Lymphoma | Mycosis Fungoides | Lymphoma, Primary Cutaneous Anaplastic Large Cell | CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma | Lymphomatoid Papulosis | Skin Lymphoma | Cutaneous Lymphomas | Hematologic Disorder

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Active, not recruiting

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Thyroid Cancer

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Lymphoma

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Lymphoma

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

Leukemia

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer

Bladder Cancer

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

Rectal Cancer

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery

Hepatocellular Carcinoma | Liver Cancer

United States

Clinical Trials Sponsored by C3i Center Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations